Picture of Alector logo

ALEC — Alector Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

Momentum

Relative Strength (%)
1m-31.21%
3m-30.54%
6m-52.25%
1yr-22.58%
Volume Change (%)
10d/3m+20.2%
Price vs... (%)
52w High-63%
50d MA-24.22%
200d MA-30.05%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)32.52
PEG Ratio (f)0.68
EPS Growth (f)91.09%
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value3.88
Price to Tang. Book3.88
Price to Free Cashflow4.39
Price to Sales6.58
EV to EBITDAn/a

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-4.77%
Return on Equity-10.18%
Operating Margin-17.37%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Latest News & Insights for ALEC

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202131st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2021 / 2022

Blurred out image of Alector EPS forecast chart

Profile Summary

Alector, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration. Immuno-neurology targets immune dysfunction as a cause of multiple pathologies that are drivers of degenerative brain disorders. The Company is developing therapies designed to simultaneously counteract these pathologies by restoring healthy immune function to the brain. The Company's platform leverages large scale human genetic datasets, advanced tools in bioinformatics and imaging, and insights into neurodegeneration and immunology to identify immune system. Its platform focuses on target selection, biomarker selection and patient selection. Its product portfolio includes AL001, AL002, AL003, and AL101. Its AL001 targets frontotemporal dementia carrying a progranulin (FTD-GRN).

Directors

Last Annual
December 31st, 2020
Last Interim
September 30th, 2021
Incorporated
September 19th, 2017
Public Since
February 7th, 2019
No. of Shareholders
17
No. of Employees
185
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
81,276,097

ALEC Share Price Performance

Similar to ALEC

2Seventy Bio

us flag iconNASDAQ Global Select Market

Picture of 4D Molecular Therapeutics logo

4D Molecular Therapeutics

us flag iconNASDAQ Global Select Market

Picture of AbCellera Biologics logo

AbCellera Biologics

us flag iconNASDAQ Global Select Market

AbSci

us flag iconNASDAQ Global Select Market

Picture of ACADIA Pharmaceuticals logo

ACADIA Pharmaceuticals

us flag iconNASDAQ Global Select Market

FAQ

Or unlock with your email

Or unlock with your email